For pharmaceutical companies, compliance is not simply a matter of ensuring that promotional materials are scientifically accurate. Companies must first determine whether a communication qualifies as advertising, identify the intended audience and verify whether the medicinal product may lawfully be promoted at all.
Hungary follows the fundamental principles established by European Union pharmaceutical legislation. However, EU-level rules operate alongside national legislation that determines how pharmaceutical promotion is regulated and enforced in practice. Companies entering the Hungarian market must therefore consider both the common European framework and the specific requirements of Hungarian law.
The principal national legislation is Act XCVIII of 2006 on the General Rules on the Safe and Economical Supply of Medicinal Products and Medical Devices and on the Distribution of Medicinal Products. The competent authority (currently the National Centre for Public Health and Pharmacy, but soon to be re-established in the form of an independent National Institute of Pharmacy) plays an important role in supervising pharmaceutical promotion and related activities. The authority's responsibilities include oversight of promotional practices directed at healthcare professionals and compliance with the rules governing medicinal product advertising. Furthermore, applicable industry codes also impose additional ethical standards on companies that are members of relevant industry associations or have undertaken to comply with those standards.
For companies entering the Hungarian market, understanding these requirements is essential to reducing regulatory risk and implementing compliant marketing strategies.
Promotion and advertisements must always follow the authorised status of the product
Under the EU framework and the Hungarian rules medicinal products must not be promoted or advertised before the required marketing authorisation has been granted or in a manner inconsistent with the authorised indications. Off-label communication in promotional material is strictly prohibited. Companies must distinguish legitimate scientific discussion of emerging evidence from promotional claims concerning unauthorised uses.
Advertising or promoting a medicinal product for an indication that is not authorised in Hungary presents significant regulatory risk. The same concern arises where a communication implies that the product should be used in a patient population, dosage regimen or treatment setting not covered by the authorised product information. This does not mean that healthcare professionals cannot engage in independent medical decision-making or discuss scientific developments, however any such communication has to be distinctly separated from promotional content and commercial practices.
What qualifies as pharmaceutical advertising?
Hungarian law distinguishes between advertising to the general public and professional promotion to healthcare professionals. As a general rule, advertising to the public is permitted only for non-prescription (OTC) medicinal products that are not reimbursed under the Hungarian social security system. Advertising prescription-only medicinal products to the general public is prohibited.
Mandatory content of consumer advertising
Permitted consumer advertising must comply with specific content requirements. Advertisements must, among other things: (i) clearly identify the advertised product as a medicinal product; (ii) state the medicinal product's name; (iii) include the international name of the active substance where the product contains only one active substance; (iv) encourage the correct use of the medicinal product; (v) present the product consistently with its authorised product information; (vi) include the prescribed warning and information necessary for correct use; (vii) clearly direct the audience to read the package leaflet or the relevant product information.
Consumer advertisements must include the specific warning required by applicable Hungarian rules on advertising medicinal products. The warning should not be treated as a purely technical requirement. Its prominence must be considered alongside the overall presentation of the advertisement. For audiovisual advertising, for example, the company should assess whether the warning remains readable or audible for the required period. For digital advertisements, the format, screen size and placement should not undermine its accessibility.
Prohibited claims and misleading presentations in advertisements
Hungarian pharmaceutical advertising rules also restrict a range of claims and presentation techniques. Consumer advertising must not suggest that a medicinal product: (i) guarantees recovery; (ii) has no side effects; (iii) makes medical consultation or treatment unnecessary; (iv); is essentially a food or cosmetic product; (v) is effective or safe solely because its ingredients are natural; (vi) prevents harm to health in a manner that creates inappropriate fear or pressure.
Advertising must also avoid presentations that may encourage erroneous self-diagnosis through detailed descriptions of medical histories or that depict illness and treatment in a misleading, alarming or inappropriate manner. These restrictions affect both express claims and the overall impression created by the advertisement.
Promotion of medicinal products to healthcare professionals
Professional pharmaceutical promotion is subject to a different set of rules from consumer advertising. Under the Hungarian framework, medicinal product promotion directed at healthcare professionals is generally understood as commercial practice relating to the composition, effects or use of a medicinal product that is addressed exclusively to persons with the relevant healthcare qualifications and authority to prescribe, supply, train in the use of or distribute the relevant product. The intended audience is therefore an important element of the regulatory assessment.
A company intending to conduct pharmaceutical promotional activities must notify the authority in accordance with the applicable rules. The company engaging a promotional representative must also provide the required information to the authority within the statutory period following the establishment of the relevant relationship.
Promotional materials for healthcare professionals
Promotional materials must be consistent with the authorised product information and must not be misleading. Claims concerning efficacy, safety, dosage, indications, contraindications and adverse reactions should be accurate and appropriately supported. The EU framework requires advertising directed at persons qualified to prescribe or supply medicinal products to include essential information consistent with the Summary of Product Characteristics (SmPC).
Hungarian requirements and applicable industry codes impose further requirements concerning the information that must appear in professional materials. Depending on the type of communication, the company may need to include (i) the medicinal product's name and pharmaceutical form; (ii) its active substance and strength; (iii) the authorised indications; (iv); dosage and administration; (v) relevant contraindications and adverse reactions; (vi) the date of preparation or last revision; (vii) references supporting clinical claims; (viii) pricing or reimbursement information where required; (ix) the identity and contact details of the relevant local representative or marketing authorisation holder; (x) unique identifiers of the promotional material. The precise requirements depend on the medium, audience and applicable legal provisions.
Scientific evidence and comparative claims
Companies should ensure that claims are supported by appropriate evidence and that the material does not distort the significance of clinical findings. Comparisons between medicinal products require particular scrutiny. A comparative claim should be fair, accurate, relevant and supported by suitable evidence.
Integrate adverse event reporting
Pharmaceutical promotional activities may result in the receipt of information concerning suspected adverse reactions or other product safety issues. Representatives, marketing personnel, social media teams and medical information staff should understand how to identify and escalate potentially reportable information under the company's pharmacovigilance procedures. The precise reporting obligations and timelines depend on the applicable pharmacovigilance framework and the company's role in the relevant process.
Potential consequences of non-compliance
The consequences of unlawful pharmaceutical advertising or promotion depend on the applicable legal basis, the nature of the infringement and the circumstances of the case. Potential consequences may include regulatory proceedings, financial penalties, requirements to cease or correct a campaign, reputational damage and disruption to commercial activities. Other consequences may arise under applicable consumer protection, competition, or industry-code frameworks. Prior review is generally more efficient than responding to a problem after the campaign has been distributed.
Conclusion
Advertising medicinal products in Hungary requires a structured understanding of the rules governing consumer advertising, professional promotion and related commercial practices. The central principles are that promotion must be consistent with the authorised status of the product and communications must be appropriate for their intended audience.
How we assist
We advise Hungarian and international life sciences companies on:
- Hungarian and EU rules governing the advertising and promotion of medicinal products
- regulatory requirements for prescription-only and OTC medicines
- review of promotional materials, advertising campaigns and communications with healthcare professionals
- compliance with applicable requirements on advertising claims, mandatory information and promotional content
- the interaction between pharmaceutical advertising rules, EU law, consumer protection and data protection requirements
- regulatory risk assessment, compliance procedures and support in interactions with the competent Hungarian authorities
Our approach combines in-depth regulatory knowledge with practical industry insight, helping life sciences companies navigate Hungary’s pharmaceutical advertising framework, mitigate compliance risks and develop promotional strategies that support their commercial objectives while meeting applicable legal requirements.